A multi-centre phase 3 study comparing efficacy and safety of Bemfola® versus Gonal-f® in women undergoing ovarian stimulation for IVF

Reproductive BioMedicine Online

Volumn 30, Issue 5, 2015, Pages 504-513

  Rettenbacher, M ^a   Andersen, A N ^b   Garcia Velasco, J A ^c   Sator, M ^d   Barri, P ^e   Lindenberg, S ^f   Van Der Ven, K ^g   Khalaf, Y ^h   Bentin Ley, U ⁱ   Obruca, A ^j   Tews, G ^k   Schenk, M ^l   Strowitzki, T ^m   Narvekar, N ⁿ   Sator, K ^o   Imthurn, B ^p  

^a Finox AG   (Switzerland)

^b Rigshospitalet   (Denmark)

^c IVI Madrid   (Spain)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e INSTITUT UNIVERSITARI DEXEUS   (Spain)

^f Section for Human Reproduction   (Denmark)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ Dansk Fertilitetsklinik   (Denmark)

^j Kinderwunschzentrum Goldenes Kreuz   (Austria)

^k KEPLER UNIVERSITY HOSPITAL   (Austria)

^l Das Kinderwunsch Institut   (Austria)

^m UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁿ KING S COLLEGE HOSPITAL   (United Kingdom)

^o Fertilitätszentrum Döbling   (Austria)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

IVF ICSI; oocytes retrieved; ovarian stimulation; r FSH

Indexed keywords

ESTRADIOL; FOLLITROPIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CELL COUNT; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; GERMINAL VESICLE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMPLANTATION; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; METAPHASE; MULTICENTER STUDY; OBSTETRIC PROCEDURE; OOCYTE RETRIEVAL; OVARIAN STIMULATION; OVARY HYPERSTIMULATION; PHASE 3 CLINICAL TRIAL; PREGNANCY OUTCOME; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; CLINICAL TRIAL; OVULATION INDUCTION; PROCEDURES;

FEMALE; FERTILIZATION IN VITRO; HUMANS; OVULATION INDUCTION;

EID: 84928927921     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/j.rbmo.2015.01.005     Document Type: Article

References (21)

1. American Society for Reproductive Medicine (ASRM) Revised American Society for Reproductive Medicine classification of endometriosis: 1996 Fertil. Steril 67 1997 817
2. Andersen A.N., Devroey P., and Arce J.C. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blinded controlled trial Hum. Reprod 12 2006 3217
3. Balen A., Platteau P., Andersen A.N., Helmgaard L., Arce J.C. Bravelle Ovulation Induction (BOI) Study Group Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomised controlled non-inferiority trial Hum. Reprod 22 2007 1816
4. Bergh C., Howles C.M., Borg K., Hamberger L., Josefsson B., Nilsson L., and Wikland M. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-f) versus highly purified urinary FSH (Metrodin® HP): results of a randomized comparative study in women undergoing assisted reproductive techniques Hum. Reprod 12 1997 2133
5. Bühler K., and Naether O. A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study Gynecol. Endocrinol 27 2011 650
6. Engelberg A.B., Kesselheim A.S., and Avorn J. Balancing innovation, access, and profits - market exclusivity for biologics N. Engl. J. Med 361 2009 1917
7. European Medicines Agency European Public Assessment Report Bemfola http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002615/WC500166820.pdf 2014 accessed 14.10.29
8. Frydman R., Howles C.M., and Truong F. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-f®) with highly purified urinary FSH (Metrodin® HP) in woman undergoing assisted reproductive techniques including intracytoplasmic sperm injection Hum. Reprod 15 2000 520
9. Jayaprakasan K., Hopkisson J., Campbell B., Johnson I., Thornton J., and Raine-Fenning N. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count BJOG 117 2010 853
10. La Marca A., and Sunkary S.K. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice Hum. Repro 20 2013 124
11. Lee T.H., Liu C.H., Huang C.C., Wu Y.L., Shih Y.T., Ho H.N., Yang Y.S., and Lee M. Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles Hum. Reprod 23 2008 160
12. Lunenfeld B. Historical perspectives in gonadotrophin therapy Hum. Reprod. Update 10 2004 453
13. Nelson S.M., Anderson R.A., Broekmans F.J., Raine-Fenning N., Fleming R., and La Marca A. Anti-Müllerian hormone: clairvoyance or crystal clear? Hum. Reprod 27 2012 631
14. Olivennes F., Howles C.M., Borini A., Germond M., Trew G., Wikland M., Zegers-Hochschild F., Saunders H., and Alam V. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study Reprod. Biomed. Online 18 2009 195
15. Recombinant Human FSH Study Group Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilisation Fertil. Steril 63 1995 77
16. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum. Reprod 19 2004 41 47
17. Schats R., Sutter P.D., Bassil S., Kremer J.A., Tournaye H., and Donnez J. Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH Hum. Reprod 15 2000 1691
18. Schellekens H., and Moors E. Clinical comparability and European biosimilar regulations Nat. Biotechnol 28 2010 28
19. Szolar O.H.J., Stranner S., Zinoecker I., Mudde G.C., Himmler G., Waxenecker G., and Nechansky A. Qualification and application of a surface plasmon resonance-based assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody J. Pharm. Biomed. Anal 41 2007 1347
20. The Practice Committee of the American Society for Reproductive Medicine Ovarian hyperstimulation syndrome Fertil. Steril 82 1 Suppl. 2004 S81 S86
21. Weise M., Bielsky M.C., De Smet K., Ehmann F., Ekman N., Giezen T.J., Gravanis I., Heim H.K., Heinonen E., Ho K., Moreau A., Narayanan G., Kruse N.A., Reichmann G., Thorpe R., van Aerts L., Vleminckx C., Wadhwa M., and Schneider C.K. Biosimilars: what clinicians should know Blood 120 2012 5111